Gary Adams

Dr. Gary Adams

Centre for International Diabetes Education and Research (CIDER), The University of Nottingham, UK
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2016 in Nature Biotechnology
Verified
Journal Article
Closed access
SUSelman Uluisik
Selman Uluisik
NCNatalie H Chapman
Natalie H Chapman
RSRebecca Smith
Rebecca Smith
MPMervin Poole
Mervin Poole
Gary AdamsGary Adams
Gary Adams
GSGraham B Seymour
Graham B Seymour

1 January 2017 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
GKGeorge Kerrison
George Kerrison
RGRichard B. Gillis
Richard B. Gillis
SJShahwar I. Jiwani
Shahwar I. Jiwani
QAQushmua Alzahrani
Qushmua Alzahrani
SKSamil Kok
Samil Kok
Gary AdamsGary Adams
Gary Adams
Diabetes prevalence is increasing exceptionally worldwide and with this come associated healthcare costs. The primary outcome of this systematic review was to assess glycaemic control and incidence of Type 2 diabetes mellitus (T2DM) diagnosis after exercise and dietary intervention (measured with any validated scale). The secondary outcome assessed body mass index change, weight change, and physical exercise capacity after diet and exercise intervention (measured with any validated scale). 1,780 studies were identified from searching electronic databases. Relevant studies went through a selection process. The inclusion criteria for all studies were people with prediabetes diagnosed by either impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). Lifestyle adaptation reduced the incidence of diabetes development more than standard treatment. Furthermore, better glycaemic control, improved physical exercise capacity, and increased weight reduction were observed with lifestyle intervention over standard treatment. Finally, improvements over the long term deteriorated, highlighting problems with long-term adherence to lifestyle changes. Overall, cumulative incidence of diabetes is drastically reduced in the intervention groups compared to control groups (standard care). Furthermore, glycaemic control was improved in the short term, with many participants reverting to normoglycaemia.

1 May 2018 in Heliyon
Verified
Journal Article
Open access
PAP. Adiewere
P. Adiewere
RGR.B. Gillis
R.B. Gillis
SJS. Imran Jiwani
S. Imran Jiwani
AMA. Meal
A. Meal
ISI. Shaw
I. Shaw
Gary AdamsGary Adams
Gary Adams
The World Health Organization (WHO) states that diabetic foot ulcers (DFU) are associated with disability, death among patients with diabetes and substantial costs, if not prevented or managed effectively. The aim here is to examine the effectiveness of patient education in preventing and reducing the incidence or recurrence of adult DFU and amputation. A systematic review and meta-analysis of randomised clinical trials (RCTs) in adults aged 18+ who have diabetes mellitus (type 1 or type 2) or DFU. CINAHL, EMBASE, MEDLINE, PSYCINFO, Cochrane Library and Evidence-Based Nursing, National Library for Health, Medica and Google Scholar were searched. Only English language studies were considered. Databases were searched from their inception to September 2017. Six RCTs met the inclusion criteria. Only five RCTs reported on the incidence of DFU whilst only two reported on amputation rates. There was no advantage of combining different educational approaches in preventing/reducing DFU, relative risk (RR) of 0.50 (95%CI 0.21, 1.17) (P = 0.11). Two RCTs based on foot care education alone were compared with usual care; the result showed a non-significant effect (P = 0.57) with high heterogeneity of 77%.Analysis based on intensive versus brief educational approach showed a statistically reduced risk of incidence of DFU in the intervention group when compared to the control group; (RR, 0.37, 95%CI 0.14, 1.01) (P = 0.05) with high heterogeneity of 91%. The intensive educational intervention was associated with reduced incidence of DFU.

23 February 2007 in Diabetes/Metabolism Research and Reviews
Verified
Journal Article
Closed access
PDF file
JLJane Langley
Jane Langley
Gary AdamsGary Adams
Gary Adams

1 October 2012 in Food Chemistry
Verified
Journal Article
Closed access
Gary AdamsGary Adams
Gary Adams
SIShahwar Imran
Shahwar Imran
SWSheng Wang
Sheng Wang
AMAbubaker Mohammad
Abubaker Mohammad
MKM. Samil Kok
M. Samil Kok
Stephen Ernest HardingStephen Ernest Harding
Stephen Ernest Harding

22 January 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
VDVlad Dinu
Vlad Dinu
YLYudong Lu
Yudong Lu
NWNicola Weston
Nicola Weston
RLRyan Lithgo
Ryan Lithgo
HCHayley Coupe
Hayley Coupe
Stephen Ernest HardingStephen Ernest Harding
Stephen Ernest Harding
Vancomycin, a branched tricyclic glycosylated peptide antibiotic, is a last-line defence against serious infections caused by staphylococci, enterococci and other Gram-positive bacteria. Orally-administered vancomycin is the drug of choice to treat pseudomembranous enterocolitis in the gastrointestinal tract. However, the risk of vancomycin-resistant enterococcal infection or colonization is significantly associated with oral vancomycin. Using the powerful matrix-free assay of co-sedimentation analytical ultracentrifugation, reinforced by dynamic light scattering and environmental scanning electron microscopy, and with porcine mucin as the model mucin system, this is the first study to demonstrate strong interactions between vancomycin and gastric and intestinal mucins, resulting in very large aggregates and depletion of macromolecular mucin and occurring at concentrations relevant to oral dosing. In the case of another mucin which has a much lower degree of glycosylation (~60%) – bovine submaxillary mucin - a weaker but still demonstrable interaction is observed. Our demonstration - for the first time - of complexation/depletion interactions for model mucin systems with vancomycin provides the basis for further study on the implications of complexation on glycopeptide transit in humans, antibiotic bioavailability for target inhibition, in situ generation of resistance and future development strategies for absorption of the antibiotic across the mucus barrier.